Katalin Karikó - Revision history

Isi96: Rescuing 55 sources and tagging 0 as dead.) #IABot (v2.0.9.5

2024-10-07T01:19:32Z

Rescuing 55 sources and tagging 0 as dead.) #IABot (v2.0.9.5

SPECIFICO: /* Career */ not a restaurant.

2024-09-29T07:37:56Z

Career: not a restaurant.

← Previous revision		Revision as of 07:37, 29 September 2024
Line 43:		Line 43:

	== Career ==		== Career ==
	Between 1985 and 1988, Karikó ~~served as~~ a postdoctoral fellow at [[Temple University]] in Philadelphia. Karikó participated in a clinical trial in which patients with AIDS, [[hematologic disease]]s, and [[chronic fatigue syndrome]] were treated with [[RNA#Double-stranded RNA\|double-stranded RNA]] (dsRNA). At the time, this was considered groundbreaking research, as the molecular mechanism of [[interferon]] induction by dsRNA was not known, although the antiviral and [[antineoplastic]] effects of interferons were well-documented.<ref>{{Cite web \|last=Schwarz-Romond \|first=Thomas \|date=7 November 2016 \|title=Transforming RNA research into future treatments: Q&A with 2 biotech leaders \|url=https://www.elsevier.com/connect/archive/transforming-rna-research-into-future-treatments-q-and-a-with-2-biotech-leaders \|access-date=27 April 2020 \|website=Elsevier Connect \|language=en}}</ref>		Between 1985 and 1988, Karikó was a postdoctoral fellow at [[Temple University]] in Philadelphia. Karikó participated in a clinical trial in which patients with AIDS, [[hematologic disease]]s, and [[chronic fatigue syndrome]] were treated with [[RNA#Double-stranded RNA\|double-stranded RNA]] (dsRNA). At the time, this was considered groundbreaking research, as the molecular mechanism of [[interferon]] induction by dsRNA was not known, although the antiviral and [[antineoplastic]] effects of interferons were well-documented.<ref>{{Cite web \|last=Schwarz-Romond \|first=Thomas \|date=7 November 2016 \|title=Transforming RNA research into future treatments: Q&A with 2 biotech leaders \|url=https://www.elsevier.com/connect/archive/transforming-rna-research-into-future-treatments-q-and-a-with-2-biotech-leaders \|access-date=27 April 2020 \|website=Elsevier Connect \|language=en}}</ref>

	In 1988, Karikó accepted a job at [[Johns Hopkins University]] without first informing her lab advisor Suhadolnik of her intention to leave Temple, as recounted in [[Gregory Zuckerman]]'s 2021 book ''A Shot to Save the World''. Suhadolnik told her that if she went to Johns Hopkins, he would have her [[deportation\|deported]], and subsequently reported her to U.S. immigration authorities, claiming that she was "illegally" in the United States. In the time it took her to successfully challenge the resulting extradition order, Johns Hopkins withdrew the job offer. Suhadolnik "continued bad-mouthing Karikó, making it impossible for her to get a new position" at other institutions, until she met a researcher at [[Bethesda Naval Hospital]] who "had his own difficult history with Suhadolnik".<ref name=Zuckerman2021>[https://books.google.com/books?id=mio3EAAAQBAJ&pg=PA69 ''A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine'']; p. 69; by [[Gregory Zuckerman]]; published 26 October 2021, by [[Penguin Books]]</ref> Karikó subsequently confirmed that the incident had happened as Zuckerman described, but emphasized that "more importantly I was always grateful to [Suhadolnik for] sending me the [[U.S. Immigration and Customs Enforcement\|IAP66 form]] in 1985, for the opportunity he gave me to work in his lab", noting that "when I gave a lecture [at Temple, a] couple of years later, I thanked him for the science I learned from him."<ref name=satpaper20211211>[https://www.thesaturdaypaper.com.au/news/health/2021/12/11/part-one-the-true-story-the-covid-19-vaccines/163914120013056 Part one: The true story of the COVID-19 vaccines], by Rick Morton, in ''[[The Saturday Paper]]''; published 11 December 2021 (no. 379); retrieved 4 October 2023</ref> From 1988 to 1989, she worked at the [[Uniformed Services University of the Health Sciences]] in [[Bethesda, Maryland]]<ref name="Neill">{{cite journal \|last1=Neill \|first1=Ushma S. \|title=A conversation with Katalin Karikó \|journal=The Journal of Clinical Investigation \|date=2021 \|volume=131 \|issue=21 \|pages=e155559 \|doi=10.1172/JCI155559 \|pmid=34720092 \|pmc=8553550 \|issn=0021-9738}}</ref> where she worked with signal protein interferons.<ref name="Hargittai"/>		In 1988, Karikó accepted a job at [[Johns Hopkins University]] without first informing her lab advisor Suhadolnik of her intention to leave Temple, as recounted in [[Gregory Zuckerman]]'s 2021 book ''A Shot to Save the World''. Suhadolnik told her that if she went to Johns Hopkins, he would have her [[deportation\|deported]], and subsequently reported her to U.S. immigration authorities, claiming that she was "illegally" in the United States. In the time it took her to successfully challenge the resulting extradition order, Johns Hopkins withdrew the job offer. Suhadolnik "continued bad-mouthing Karikó, making it impossible for her to get a new position" at other institutions, until she met a researcher at [[Bethesda Naval Hospital]] who "had his own difficult history with Suhadolnik".<ref name=Zuckerman2021>[https://books.google.com/books?id=mio3EAAAQBAJ&pg=PA69 ''A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine'']; p. 69; by [[Gregory Zuckerman]]; published 26 October 2021, by [[Penguin Books]]</ref> Karikó subsequently confirmed that the incident had happened as Zuckerman described, but emphasized that "more importantly I was always grateful to [Suhadolnik for] sending me the [[U.S. Immigration and Customs Enforcement\|IAP66 form]] in 1985, for the opportunity he gave me to work in his lab", noting that "when I gave a lecture [at Temple, a] couple of years later, I thanked him for the science I learned from him."<ref name=satpaper20211211>[https://www.thesaturdaypaper.com.au/news/health/2021/12/11/part-one-the-true-story-the-covid-19-vaccines/163914120013056 Part one: The true story of the COVID-19 vaccines], by Rick Morton, in ''[[The Saturday Paper]]''; published 11 December 2021 (no. 379); retrieved 4 October 2023</ref> From 1988 to 1989, she worked at the [[Uniformed Services University of the Health Sciences]] in [[Bethesda, Maryland]]<ref name="Neill">{{cite journal \|last1=Neill \|first1=Ushma S. \|title=A conversation with Katalin Karikó \|journal=The Journal of Clinical Investigation \|date=2021 \|volume=131 \|issue=21 \|pages=e155559 \|doi=10.1172/JCI155559 \|pmid=34720092 \|pmc=8553550 \|issn=0021-9738}}</ref> where she worked with signal protein interferons.<ref name="Hargittai"/>

GuardianH: ce

2024-09-24T00:29:29Z

← Previous revision		Revision as of 00:29, 24 September 2024
Line 12:		Line 12:
	\| other_names = Kati Kariko<ref name="Kolata" />		\| other_names = Kati Kariko<ref name="Kolata" />
	\| citizenship = {{hlist\|Hungary\|United States}}		\| citizenship = {{hlist\|Hungary\|United States}}
	\| education = [[University of Szeged]] (BSc, PhD)		\| education = [[University of Szeged]] ([[BSc]], [[PhD]])
	\| known_for = [[mRNA]] technology in [[immunology]] and therapies		\| known_for = [[mRNA]] technology in [[immunology]] and therapies
	\| spouse = Béla Francia		\| spouse = Béla Francia

Nandwanirajesh: Inclusion in Time list

2024-09-19T16:02:47Z

Inclusion in Time list

← Previous revision		Revision as of 16:02, 19 September 2024
Line 84:		Line 84:

	In 2023, Karikó was inducted into the [[National Inventors Hall of Fame]] for her research into messenger RNA.<ref>{{Cite web \|last=Singhi \|first=Shaurya \|title=Penn researchers behind mRNA vaccine inducted into the American National Inventors Hall of Fame \|url=https://www.thedp.com/article/2023/02/penn-weissman-kariko-national-inventors-hall-of-fame-mrna \|access-date=21 July 2023 \|website=www.thedp.com \|language=en-us}}</ref>		In 2023, Karikó was inducted into the [[National Inventors Hall of Fame]] for her research into messenger RNA.<ref>{{Cite web \|last=Singhi \|first=Shaurya \|title=Penn researchers behind mRNA vaccine inducted into the American National Inventors Hall of Fame \|url=https://www.thedp.com/article/2023/02/penn-weissman-kariko-national-inventors-hall-of-fame-mrna \|access-date=21 July 2023 \|website=www.thedp.com \|language=en-us}}</ref>

			Karikó was named in the 2024 Time 100 influential people in health. <ref>{{Cite web \|last=Park \|first=Alice \|date=2024-05-02 \|title=Katalin Kariko and Drew Weissman \|url=https://time.com/6966810/kariko-weissman/ \|access-date=2024-09-19 \|website=TIME \|language=en}}</ref>

	== Personal life ==		== Personal life ==

Cmichel67: better version

2024-09-19T14:25:49Z

better version

← Previous revision		Revision as of 14:25, 19 September 2024
Line 4:		Line 4:
	{{Infobox scientist		{{Infobox scientist
	\| name = Katalin Karikó		\| name = Katalin Karikó
	\| image = Katalin Karikó by Michel 2024 01.jpg		\| image = Katalin Karikó by Christopher Michel in 2024 7.jpg
	\| caption = Karikó in 2024		\| caption = Karikó in 2024
	\| birth_date = {{birth date and age\|1955\|1\|17\|df=y}}		\| birth_date = {{birth date and age\|1955\|1\|17\|df=y}}

Cmichel67: Updated Photo

2024-09-18T21:12:05Z

Updated Photo

← Previous revision		Revision as of 21:12, 18 September 2024
Line 4:		Line 4:
	{{Infobox scientist		{{Infobox scientist
	\| name = Katalin Karikó		\| name = Katalin Karikó
	\| image = Katalin Karikó by Michel ~~3662809-16-24~~.jpg		\| image = Katalin Karikó by Michel 2024 01.jpg
	\| caption = Karikó in 2024		\| caption = Karikó in 2024
	\| birth_date = {{birth date and age\|1955\|1\|17\|df=y}}		\| birth_date = {{birth date and age\|1955\|1\|17\|df=y}}

Cmichel67: Updated Photo

2024-09-18T13:42:46Z

Updated Photo

← Previous revision		Revision as of 13:42, 18 September 2024
Line 4:		Line 4:
	{{Infobox scientist		{{Infobox scientist
	\| name = Katalin Karikó		\| name = Katalin Karikó
	\| image = Katalin Karikó ~~in 2024~~ by ~~Christopher~~ Michel 01.jpg		\| image = Katalin Karikó by Michel 3662809-16-24.jpg
	\| caption = Karikó in 2024		\| caption = Karikó in 2024
	\| birth_date = {{birth date and age\|1955\|1\|17\|df=y}}		\| birth_date = {{birth date and age\|1955\|1\|17\|df=y}}

Cmichel67: Updated Photo

2024-09-17T13:31:14Z

Updated Photo

← Previous revision		Revision as of 13:31, 17 September 2024
Line 4:		Line 4:
	{{Infobox scientist		{{Infobox scientist
	\| name = Katalin Karikó		\| name = Katalin Karikó
	\| image = Katalin Karikó at ~~the~~ ~~United~~ ~~States~~ ~~Embassy~~ ~~Sweden, 2023 Nobel Reception (cropped)~~.jpg		\| image = Katalin Karikó in 2024 by Christopher Michel 01.jpg
	\| caption = Karikó in ~~2023~~		\| caption = Karikó in 2024
	\| birth_date = {{birth date and age\|1955\|1\|17\|df=y}}		\| birth_date = {{birth date and age\|1955\|1\|17\|df=y}}
	\| birth_place = [[Szolnok]], [[Hungarian People's Republic\|Hungary]]		\| birth_place = [[Szolnok]], [[Hungarian People's Republic\|Hungary]]

Preimage: /* Career */ Add citation for 2005 Nature and Science rejections + remove failed verification tag

2024-09-06T12:04:25Z

Career: Add citation for 2005 Nature and Science rejections + remove failed verification tag

← Previous revision		Revision as of 12:04, 6 September 2024
Line 55:		Line 55:
	{{blockquote\|Kate was really just unbelievable... She was always incredibly inquisitive. She read voraciously. She would always know the latest technology or the latest paper, even if it was in a totally different area, and she'd put two and two together and say, 'Well why don't we do this?' Or, 'Why don't we try this formulation?' \|author= Elliot Barnathan<ref name="George"/>}}		{{blockquote\|Kate was really just unbelievable... She was always incredibly inquisitive. She read voraciously. She would always know the latest technology or the latest paper, even if it was in a totally different area, and she'd put two and two together and say, 'Well why don't we do this?' Or, 'Why don't we try this formulation?' \|author= Elliot Barnathan<ref name="George"/>}}

	Before 2005, a major problem with the proposed therapeutic use of mRNA was that in vivo use led to inflammatory reactions.<ref name="Hogan"/> A key insight came about when Karikó focused on why [[transfer RNA]] (tRNA), used as a [[Scientific control\|control]] in an experiment, did not provoke the same immune reaction as mRNA.<ref name="Kolata" /> A series of landmark studies beginning in 2005 demonstrated that while synthetic mRNA was highly inflammatory, tRNA was noninflammatory. Karikó and Weissman determined how specific nucleoside modifications in mRNA led to a reduced immune response:<ref name="Wired2020" /><ref name="Hogan">{{cite journal \|last1=Hogan \|first1=Michael J. \|last2=Pardi \|first2=Norbert \|title=mRNA Vaccines in the COVID-19 Pandemic and Beyond \|journal=Annual Review of Medicine \|date=27 January 2022 \|volume=73 \|issue=1 \|pages=17–39 \|doi=10.1146/annurev-med-042420-112725 \|pmid=34669432 \|s2cid=239050929 \|language=en \|issn=0066-4219\|doi-access=free }}</ref> by replacing [[uridine]] with [[pseudouridine]].<ref>{{cite journal \|last1=Wilson \|first1=Barnabas \|last2=Geetha \|first2=Kannoth Mukundan \|title=Lipid nanoparticles in the development of mRNA vaccines for COVID-19 \|journal=Journal of Drug Delivery Science and Technology \|date=2022 \|volume=74 \|pages=103553 \|doi=10.1016/j.jddst.2022.103553 \|pmid=35783677 \|pmc=9238147 \|issn=1773-2247}}</ref> Their key finding of a chemical modification of mRNA to render it non-immunogenic was rejected by the journals ''[[Nature (journal)\|Nature]]'' and ''[[Science (journal)\|Science]]'',~~{{failed verification\|date=October 2023}}~~ but eventually accepted by the publication ''[[Immunity (journal)\|Immunity]]''.<ref name=":5" />		Before 2005, a major problem with the proposed therapeutic use of mRNA was that in vivo use led to inflammatory reactions.<ref name="Hogan"/> A key insight came about when Karikó focused on why [[transfer RNA]] (tRNA), used as a [[Scientific control\|control]] in an experiment, did not provoke the same immune reaction as mRNA.<ref name="Kolata" /> A series of landmark studies beginning in 2005 demonstrated that while synthetic mRNA was highly inflammatory, tRNA was noninflammatory. Karikó and Weissman determined how specific nucleoside modifications in mRNA led to a reduced immune response:<ref name="Wired2020" /><ref name="Hogan">{{cite journal \|last1=Hogan \|first1=Michael J. \|last2=Pardi \|first2=Norbert \|title=mRNA Vaccines in the COVID-19 Pandemic and Beyond \|journal=Annual Review of Medicine \|date=27 January 2022 \|volume=73 \|issue=1 \|pages=17–39 \|doi=10.1146/annurev-med-042420-112725 \|pmid=34669432 \|s2cid=239050929 \|language=en \|issn=0066-4219\|doi-access=free }}</ref> by replacing [[uridine]] with [[pseudouridine]].<ref>{{cite journal \|last1=Wilson \|first1=Barnabas \|last2=Geetha \|first2=Kannoth Mukundan \|title=Lipid nanoparticles in the development of mRNA vaccines for COVID-19 \|journal=Journal of Drug Delivery Science and Technology \|date=2022 \|volume=74 \|pages=103553 \|doi=10.1016/j.jddst.2022.103553 \|pmid=35783677 \|pmc=9238147 \|issn=1773-2247}}</ref> Their key finding of a chemical modification of mRNA to render it non-immunogenic was rejected by the journals ''[[Nature (journal)\|Nature]]'' and ''[[Science (journal)\|Science]]'', but eventually accepted by the publication ''[[Immunity (journal)\|Immunity]]''.<ref name=NYTNobel>{{Cite web \|title=Nobel Prize Awarded to Covid Vaccine Pioneers \|last1=Mueller \|first1=Benjamin \|last2=Kolata \|first2=Gina \|work=The New York Times \|date=2 October 2023 \|access-date=6 September 2024 \|url= https://www.nytimes.com/2023/10/02/health/nobel-prize-medicine.html \|archive-url=http://web.archive.org/web/20231002100126/https://www.nytimes.com/2023/10/02/health/nobel-prize-medicine.html \|archive-date=2 October 2023 }}</ref><ref name=":5" />

	Another important achievement by the researchers was the development of a delivery technique to package the mRNA in [[lipid nanoparticles]], a novel pharmaceutical drug delivery system for mRNA. The mRNA is injected into tiny fat droplets (lipid nanoparticles) which protect the fragile molecule until it can reach the desired area of the body.<ref name="Tudományegyetem">{{cite news \|title=Tudományegyetem Szegedi – The University of Szeged congratulates its Professor, Katalin Karikó on the Nobel Prize \|url=https://u-szeged.hu/news-and-events/2023/the-university-of-szeged?objectParentFolderId=26349 \|work=u-szeged.hu \|date=2 October 2023 \|language=en}}</ref><ref name="AAAS">{{cite web \|title=Katalin Karikó \|url=https://www.amacad.org/person/katalin-kariko \|website=American Academy of Arts & Sciences \|language=en \|date=5 October 2023}}</ref><ref name="Żak">{{cite journal \|last1=Żak \|first1=Magdalena M. \|last2=Zangi \|first2=Lior \|title=Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery \|journal=Pharmaceutics \|date=13 October 2021 \|volume=13 \|issue=10 \|pages=1675 \|doi=10.3390/pharmaceutics13101675 \|pmid=34683969 \|pmc=8538155 \|issn=1999-4923 \|doi-access=free }}</ref> They demonstrated its effectiveness in animals.<ref>{{cite web \|title=Katalin Karikó and Drew Weissman \|url=https://www.nasonline.org/programs/awards/2022-awards/Kariko-Weissman.html \|website=National Academy of Sciences}}</ref>		Another important achievement by the researchers was the development of a delivery technique to package the mRNA in [[lipid nanoparticles]], a novel pharmaceutical drug delivery system for mRNA. The mRNA is injected into tiny fat droplets (lipid nanoparticles) which protect the fragile molecule until it can reach the desired area of the body.<ref name="Tudományegyetem">{{cite news \|title=Tudományegyetem Szegedi – The University of Szeged congratulates its Professor, Katalin Karikó on the Nobel Prize \|url=https://u-szeged.hu/news-and-events/2023/the-university-of-szeged?objectParentFolderId=26349 \|work=u-szeged.hu \|date=2 October 2023 \|language=en}}</ref><ref name="AAAS">{{cite web \|title=Katalin Karikó \|url=https://www.amacad.org/person/katalin-kariko \|website=American Academy of Arts & Sciences \|language=en \|date=5 October 2023}}</ref><ref name="Żak">{{cite journal \|last1=Żak \|first1=Magdalena M. \|last2=Zangi \|first2=Lior \|title=Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery \|journal=Pharmaceutics \|date=13 October 2021 \|volume=13 \|issue=10 \|pages=1675 \|doi=10.3390/pharmaceutics13101675 \|pmid=34683969 \|pmc=8538155 \|issn=1999-4923 \|doi-access=free }}</ref> They demonstrated its effectiveness in animals.<ref>{{cite web \|title=Katalin Karikó and Drew Weissman \|url=https://www.nasonline.org/programs/awards/2022-awards/Kariko-Weissman.html \|website=National Academy of Sciences}}</ref>

220.135.22.141: /* External links */

2024-08-30T08:52:35Z

External links

← Previous revision		Revision as of 08:52, 30 August 2024
Line 130:		Line 130:
	{{2023 Nobel Prize winners}}		{{2023 Nobel Prize winners}}
	{{Hungarian Nobel Laureates}}		{{Hungarian Nobel Laureates}}
			{{Japan Prize}}
	{{Tang Prize winners}}		{{Tang Prize winners}}
	{{Breakthrough Prize laureates}}		{{Breakthrough Prize laureates}}

← Previous revision		Revision as of 12:04, 6 September 2024
Line 55:		Line 55:
	{{blockquote\|Kate was really just unbelievable... She was always incredibly inquisitive. She read voraciously. She would always know the latest technology or the latest paper, even if it was in a totally different area, and she'd put two and two together and say, 'Well why don't we do this?' Or, 'Why don't we try this formulation?' \|author= Elliot Barnathan<ref name="George"/>}}		{{blockquote\|Kate was really just unbelievable... She was always incredibly inquisitive. She read voraciously. She would always know the latest technology or the latest paper, even if it was in a totally different area, and she'd put two and two together and say, 'Well why don't we do this?' Or, 'Why don't we try this formulation?' \|author= Elliot Barnathan<ref name="George"/>}}

	Before 2005, a major problem with the proposed therapeutic use of mRNA was that in vivo use led to inflammatory reactions.<ref name="Hogan"/> A key insight came about when Karikó focused on why [[transfer RNA]] (tRNA), used as a [[Scientific control\|control]] in an experiment, did not provoke the same immune reaction as mRNA.<ref name="Kolata" /> A series of landmark studies beginning in 2005 demonstrated that while synthetic mRNA was highly inflammatory, tRNA was noninflammatory. Karikó and Weissman determined how specific nucleoside modifications in mRNA led to a reduced immune response:<ref name="Wired2020" /><ref name="Hogan">{{cite journal \|last1=Hogan \|first1=Michael J. \|last2=Pardi \|first2=Norbert \|title=mRNA Vaccines in the COVID-19 Pandemic and Beyond \|journal=Annual Review of Medicine \|date=27 January 2022 \|volume=73 \|issue=1 \|pages=17–39 \|doi=10.1146/annurev-med-042420-112725 \|pmid=34669432 \|s2cid=239050929 \|language=en \|issn=0066-4219\|doi-access=free }}</ref> by replacing [[uridine]] with [[pseudouridine]].<ref>{{cite journal \|last1=Wilson \|first1=Barnabas \|last2=Geetha \|first2=Kannoth Mukundan \|title=Lipid nanoparticles in the development of mRNA vaccines for COVID-19 \|journal=Journal of Drug Delivery Science and Technology \|date=2022 \|volume=74 \|pages=103553 \|doi=10.1016/j.jddst.2022.103553 \|pmid=35783677 \|pmc=9238147 \|issn=1773-2247}}</ref> Their key finding of a chemical modification of mRNA to render it non-immunogenic was rejected by the journals ''[[Nature (journal)\|Nature]]'' and ''[[Science (journal)\|Science]]'',~~{{failed verification\|date=October 2023}}~~ but eventually accepted by the publication ''[[Immunity (journal)\|Immunity]]''.<ref name=":5" />		Before 2005, a major problem with the proposed therapeutic use of mRNA was that in vivo use led to inflammatory reactions.<ref name="Hogan"/> A key insight came about when Karikó focused on why [[transfer RNA]] (tRNA), used as a [[Scientific control\|control]] in an experiment, did not provoke the same immune reaction as mRNA.<ref name="Kolata" /> A series of landmark studies beginning in 2005 demonstrated that while synthetic mRNA was highly inflammatory, tRNA was noninflammatory. Karikó and Weissman determined how specific nucleoside modifications in mRNA led to a reduced immune response:<ref name="Wired2020" /><ref name="Hogan">{{cite journal \|last1=Hogan \|first1=Michael J. \|last2=Pardi \|first2=Norbert \|title=mRNA Vaccines in the COVID-19 Pandemic and Beyond \|journal=Annual Review of Medicine \|date=27 January 2022 \|volume=73 \|issue=1 \|pages=17–39 \|doi=10.1146/annurev-med-042420-112725 \|pmid=34669432 \|s2cid=239050929 \|language=en \|issn=0066-4219\|doi-access=free }}</ref> by replacing [[uridine]] with [[pseudouridine]].<ref>{{cite journal \|last1=Wilson \|first1=Barnabas \|last2=Geetha \|first2=Kannoth Mukundan \|title=Lipid nanoparticles in the development of mRNA vaccines for COVID-19 \|journal=Journal of Drug Delivery Science and Technology \|date=2022 \|volume=74 \|pages=103553 \|doi=10.1016/j.jddst.2022.103553 \|pmid=35783677 \|pmc=9238147 \|issn=1773-2247}}</ref> Their key finding of a chemical modification of mRNA to render it non-immunogenic was rejected by the journals ''[[Nature (journal)\|Nature]]'' and ''[[Science (journal)\|Science]]'', but eventually accepted by the publication ''[[Immunity (journal)\|Immunity]]''.<ref name=NYTNobel>{{Cite web \|title=Nobel Prize Awarded to Covid Vaccine Pioneers \|last1=Mueller \|first1=Benjamin \|last2=Kolata \|first2=Gina \|work=The New York Times \|date=2 October 2023 \|access-date=6 September 2024 \|url= https://www.nytimes.com/2023/10/02/health/nobel-prize-medicine.html \|archive-url=http://web.archive.org/web/20231002100126/https://www.nytimes.com/2023/10/02/health/nobel-prize-medicine.html \|archive-date=2 October 2023 }}</ref><ref name=":5" />

	Another important achievement by the researchers was the development of a delivery technique to package the mRNA in [[lipid nanoparticles]], a novel pharmaceutical drug delivery system for mRNA. The mRNA is injected into tiny fat droplets (lipid nanoparticles) which protect the fragile molecule until it can reach the desired area of the body.<ref name="Tudományegyetem">{{cite news \|title=Tudományegyetem Szegedi – The University of Szeged congratulates its Professor, Katalin Karikó on the Nobel Prize \|url=https://u-szeged.hu/news-and-events/2023/the-university-of-szeged?objectParentFolderId=26349 \|work=u-szeged.hu \|date=2 October 2023 \|language=en}}</ref><ref name="AAAS">{{cite web \|title=Katalin Karikó \|url=https://www.amacad.org/person/katalin-kariko \|website=American Academy of Arts & Sciences \|language=en \|date=5 October 2023}}</ref><ref name="Żak">{{cite journal \|last1=Żak \|first1=Magdalena M. \|last2=Zangi \|first2=Lior \|title=Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery \|journal=Pharmaceutics \|date=13 October 2021 \|volume=13 \|issue=10 \|pages=1675 \|doi=10.3390/pharmaceutics13101675 \|pmid=34683969 \|pmc=8538155 \|issn=1999-4923 \|doi-access=free }}</ref> They demonstrated its effectiveness in animals.<ref>{{cite web \|title=Katalin Karikó and Drew Weissman \|url=https://www.nasonline.org/programs/awards/2022-awards/Kariko-Weissman.html \|website=National Academy of Sciences}}</ref>		Another important achievement by the researchers was the development of a delivery technique to package the mRNA in [[lipid nanoparticles]], a novel pharmaceutical drug delivery system for mRNA. The mRNA is injected into tiny fat droplets (lipid nanoparticles) which protect the fragile molecule until it can reach the desired area of the body.<ref name="Tudományegyetem">{{cite news \|title=Tudományegyetem Szegedi – The University of Szeged congratulates its Professor, Katalin Karikó on the Nobel Prize \|url=https://u-szeged.hu/news-and-events/2023/the-university-of-szeged?objectParentFolderId=26349 \|work=u-szeged.hu \|date=2 October 2023 \|language=en}}</ref><ref name="AAAS">{{cite web \|title=Katalin Karikó \|url=https://www.amacad.org/person/katalin-kariko \|website=American Academy of Arts & Sciences \|language=en \|date=5 October 2023}}</ref><ref name="Żak">{{cite journal \|last1=Żak \|first1=Magdalena M. \|last2=Zangi \|first2=Lior \|title=Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery \|journal=Pharmaceutics \|date=13 October 2021 \|volume=13 \|issue=10 \|pages=1675 \|doi=10.3390/pharmaceutics13101675 \|pmid=34683969 \|pmc=8538155 \|issn=1999-4923 \|doi-access=free }}</ref> They demonstrated its effectiveness in animals.<ref>{{cite web \|title=Katalin Karikó and Drew Weissman \|url=https://www.nasonline.org/programs/awards/2022-awards/Kariko-Weissman.html \|website=National Academy of Sciences}}</ref>